Action Pharming Group NV - PHARM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,6475 Plage de 52 semaines 0,987

Cap du marché

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

9 401 358

Actions en circulation

646 123 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-50,82

Bénéfice par action (BPA)

-0,02

Chiffre d'affairess

297,2M

Bénéfice net

-11,84M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Diversified

Site Web

www.pharming.com

Siège social

Leiden, South Holland, Nld

Fondé

1988

Pharming Group NV est coté dans le secteur Pharmaceutical Preparations de la Euronext avec le ticker PHARM. Le dernier cours de clôture d'Pharming Group NV était de -. Au cours de la dernière année, les actions de Pharming Group NV ont été négociées dans une fourchette de prix de 0,6475 € à 0,987 €.

Pharming Group NV compte actuellement 646 123 000 actions en circulation. Pharming Group NV a un ratio cours/bénéfice (ratio PE) de -50.82.

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group reports first quarter 2025 financial results and provides business update First quarter 2025 total revenues increased by 42% to...

Pharming Group reports first quarter 2025 financial results and provides business update

First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024...

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Leiden, the...

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.8375	0.987	0.83	10027135	0.91295149	DE
4	0.738	0.987	0.737	11974122	0.86788315	DE
12	0.8805	0.987	0.6555	9401358	0.81245019	DE
26	0.7165	0.987	0.6555	7320235	0.83287426	DE
52	0.849	0.987	0.6475	5684810	0.80342462	DE
156	0.77	1.419	0.6475	6371370	1.00915154	DE
260	1.35	1.4995	0.6475	6088856	1.01470822	DE

PHARM - Frequently Asked Questions (FAQ)

What is the current Pharming Group NV share price?

The current share price of Pharming Group NV is 0,00 €

How many Pharming Group NV shares are in issue?

Pharming Group NV has 646 123 000 shares in issue

What is the 1 year trading range for Pharming Group NV share price?

Pharming Group NV has traded in the range of 0,6475 € to 0,987 € during the past year

What is the PE ratio of Pharming Group NV?

The price to earnings ratio of Pharming Group NV is -50,82

What is the cash to sales ratio of Pharming Group NV?

The cash to sales ratio of Pharming Group NV is 2,02

What is the reporting currency for Pharming Group NV?

Pharming Group NV reports financial results in USD

What is the latest annual turnover for Pharming Group NV?

The latest annual turnover of Pharming Group NV is USD 297,2M

What is the latest annual profit for Pharming Group NV?

The latest annual profit of Pharming Group NV is USD -11,84M

What is the registered address of Pharming Group NV?

The registered address for Pharming Group NV is VONDELLAAN 47, LEIDEN, SOUTH HOLLAND, 2332 AA

What is the Pharming Group NV website address?

The website address for Pharming Group NV is www.pharming.com

Which industry sector does Pharming Group NV operate in?

Pharming Group NV operates in the PHARMACEUTICAL DIVERSIFIED sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MLPHWPhone Web	1,12 € (40,00%)	3,53k
ALCBICrypto Blockchain Industries	0,47 € (27,03%)	2,37M
MLCOUCourbet	1,42 € (20,34%)	2
ALNOVNovacyt	0,534 € (16,72%)	959,99k
BNBSTonner Drones	0,0035 € (16,67%)	230k
ALENTEntreparticuliersCom	4,49 € (-28,73%)	230,39k
MLNMAMiguet Et Associes	0,12 € (-25,00%)	47,04k
PHXMPHAXIAM Therapeutics SA	0,215 € (-24,83%)	420,72k
ALNFLNFL Biosciences SA	1,21 € (-23,90%)	711,87k
MLCOTCoretech 5	0,04 € (-20,00%)	20,95k
ALCYBCybergun	0,0002 € (0,00%)	1,12B
BCPBanco Comercial Portugues SA	0,6622 € (1,13%)	138,31M
ALHPIHopium SA	0,0005 € (0,00%)	116,53M
ALVERVergnet	0,0005 € (-16,67%)	48,34M
ALNEVNeovacs	0,005 € (4,17%)	45,05M

Forums

Afficher les forums

Pharmin Group

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHARM)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Pharming Group NV

PHARM Dernières nouvelles

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Pharming Group to participate in April investor conferences

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

PHARM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHARM) Cours

Pharming Group NV (PHARM)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Pharming Group NV

PHARM Dernières nouvelles

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Pharming Group to participate in April investor conferences

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

PHARM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités